Index · Artikel · U.S. e-cigarette experiment inspires new medical device

U.S. e-cigarette experiment inspires new medical device

2014-05-04 2
résumén">When Noah Minskoff's mother died of lung cancer in 2007, e-cigarettes were just entering the U.S. market. Minskoff, who had just started medical school in Utah, wondered whether the devices might have saved his mother's life by helping her quit

U.S. e-cigarette experiment inspires new medical device

n">When Noah Minskoff's mother died of lung cancer in 2007, e-cigarettes were just entering the U.S. market. Minskoff, who had just started medical school in Utah, wondered whether the devices might have saved his mother's life by helping her quit smoking. Later, he sent some samples to his boyhood friend Nathan Terry, a mechanical engineer, and asked for his opinion.

Terry, who was working in Germany for the French industrial firm Areva, took apart the products to see how they were made. What he found disturbed him: at the heart of the devices were heater wires of unknown quality wrapped around bundles of glass fibers and surrounded by steel wool, silicon, plastic, tape and adhesives.

Wires between the heater, circuit board and batteries were connected with lead solder and also housed in tape and plastic. Everything was close to the heat source, meaning consumers were at risk of inhaling fiber and metal particles as well as toxic fumes from hot plastic and lead.

"There were red flags everywhere," Terry said.

Still, he liked the concept and decided to design a version of his own, avoiding the use of fiberglass, plastic and solder and sourcing his materials entirely in the United States. In 2009 he reunited with Minskoff in California and formed a company, Thermo-Essence Technologies, to sell the product.

At $300 a piece, the e-cigarette serves a niche market, albeit one with a loyal following among medical marijuana patients and smokers looking for a high-end e-cigarette. As many as 30,000 have been sold.

But what began as a quest to develop a better e-smoke has broadened into an ambitious effort to design a new medical device: an inhaler that delivers measured doses of nicotine to help people quit smoking. The technology could also eventually be used as an abuse-resistant delivery device for other drugs, including opioid painkillers.

If successful, the inhaler could become the first new smoking-cessation product to emerge from the e-cigarette field and would compete with products such as GlaxoSmithKline Plc's nicotine gum and Pfizer Inc's antismoking drug, Chantix.


To develop the inhaler, Terry formed a second company, Minusa LLC, which is based in Newtown, Connecticut. Minskoff left Thermo-Essence for family reasons and is not involved in Minusa. Terry himself is leaving Thermo-Essence, which is currently being sold, to concentrate on Minusa.

The new company obtained initial funding from Michael Breede, a commercial real-estate-turned-biotech investor whose father suffered from drug and alcohol addiction and who is eager to see an abuse-resistant painkiller device.

"This is in my wheelhouse," he said. "I think we can put a serious dent in this problem."

When Terry developed his e-cigarette he assumed the U.S. Food and Drug Administration would begin regulating the industry, as it has recently done, proposing a ban on sales to people under the age of 18 and requiring companies to register. Later it could impose product standard and quality controls.

Terry wanted to create a product that would pass any FDA inspection. He used a pure metal wire wrapped around a rod made from magnesia-stabilized zirconia, a highly durable ceramic material. Instead of meshes, tape and plastic he used novel porous ceramics and surgical-grade alloys, and instead of soldering parts together he connected them mechanically, fitting components together like Legos to complete the circuits.

He built on that design to create his drug-delivery device, known as Envi, a single-user, tamper-resistant, metered-dose inhaler.

Envi is about the size of a short cigar and comes with a spare in a case the size of a deck of playing cards.

The nicotine or other drug will come in a sealed cartridge that the patient will insert into the inhaler. To activate the device, the user will have to enter a code. The inhaler will be programed to deliver a certain amount of drug and then turn off.

When the device is returned to the case, which is required after each dose to activate it for the next dose, data on the patient's usage will be downloaded and available to be viewed electronically by the prescribing physician.

"It will only let you take your prescription," Terry said. "It will log your usage and transmit it in real time, and make it easier for the doctor to monitor and interact with the patient."


Terry, 37, who grew up on an organic farm in Ohio to "hippy commune" parents and studied mechanical engineering at the University of Idaho, faces multiple challenges.

Inhalers are typically more expensive to develop than pills, and ensuring patients get the right dose is more complicated.

"I can see a lot of barriers, but the idea is certainly interesting," said Dr. Ben Forbes, a Reader in Pharmaceutics, broadly the equivalent of a U.S. professor, at King's College London who specializes in inhaled medications.

There needs to be a good reason to target a drug to the lungs, Forbes said. Drugs that are inhaled may work faster than pills, so a device that offered quick pain relief in an abuse-resistant form would be "brilliant" if it could be produced economically, he added.

"Changes in inhaler technology have been very incremental over the years, so maybe something like this would have a place."

In the meantime, big tobacco companies are developing alternative nicotine products they hope one day will carry a "modified risk" of harm. Some are dispensed through an inhaler.

Unlike Terry's smoking-cessation device, which he plans to file with the FDA's drug division, these products would be marketed as less risky alternatives to smoking and be processed through the FDA's tobacco division.

However smokers end up using the new products will be the subject of intense research by the FDA.

Terry believes he is creating a product that will survive any market configuration. Minusa has a long way to go, and human trials may be two years off. Eventually he hopes to partner with a big drug company.

"I think we can change how drugs are delivered."

(Reporting by Toni Clarke in Washington; Editing by Michele Gershberg and Prudence Crowther)


  • Day/
  • Week/
  • Original/
  • Recommand


  • STATDOSE System-Anleitung DVD?

    Gibt es eine DVD, die zeigt, wie die STATdose Systemgerät zu montieren? Wenn ich eine Migräne hat, wirkt es meine Fähigkeit, schriftliche Anweisungen zu folgen. ----schneiden---- In Antwort auf 2010-04-25 16:22 Uhr in suzanne66 Diese youtube Links he
  • Einige Male habe ich eine hohe Herzfrequenz haben, kann diese aus durch Panikstörung verursacht werden?

    Meine Herzfrequenz wurde in den 90er Jahren die meiste Zeit blieb. Manchmal geht über 100. Ich spreche mit meinem doc er ein EKG tat und sagte, mein Herz ist in Ordnung. ----schneiden---- In Antwort auf Aussie Mel bei 2011-02-14 16.38 Es ist durchaus
  • Wie lange dauert es, Amitriptylin für Migräne zu arbeiten?

    Ich habe jetzt fast einen Monat lang 30 mg statt und ich bin immer noch schreckliche Migräne bekommen. ----schneiden---- In Antwort auf Delila bei 2011-05-16 06.18 Hallo, Sie wirklich haben sollte eine gewisse Erleichterung von jetzt erfahren. Haben
  • Metrohealth zu schneiden 450 Arbeitsplätze als Charity-Pflege steigt

    Metrohealth zu schneiden 450 Arbeitsplätze als Charity-Pflege steigt
    Metrohealth-System plant 450 Stellen als die Cleveland Sicherheitsnetz Krankenhaus steht eine zunehmende Menge an nicht durch Pflege zu schneiden. Der Stellenabbau wird erwartet, dass Patienten gerichtete Mitarbeiter zu treffen, sowie Aufsichts- und
  • Obama administration launches $1 billion healthcare drive

    Obama administration launches $1 billion healthcare drive
    WASHINGTON The Obama administration on Monday said $1 billion of federal funds allocated in last year's health reform law will go toward innovation programs designed to boost jobs and improve patient care. The announcement is the administration's lat
  • U.S. death toll rises to 24 in meningitis outbreak

    U.S. death toll rises to 24 in meningitis outbreak
    n">The death toll from a U.S. outbreak of fungal meningitis due to injections of tainted steroid medication has reached 24 with Indiana now reporting a third death, the Centers for Disease Control and Prevention said on Wednesday. Eight new cases
  • DIY Kinder-Geburtstags-Party-Dekorationen - Papier-Sternexplosion

    DIY Kinder-Geburtstags-Party-Dekorationen - Papier-Sternexplosion
    1 DIY Kinder-Geburtstags-Party-Dekorationen - Wie man ein Papier-Sternexplosion Diese schönen Dekorationen aussehen Starburst kompliziert, aber sind eigentlich super-einfach zu machen. Alles, was Sie brauchen, ist etwas Papier in Quadrate, Scheren sc
  • Super Bowl Teams "Städte See Spike in Flu Deaths

    Super Bowl Teams "Städte See Spike in Flu Deaths
    Credit: David Lee | eine neue Studie stellt fest, dass die Städte, deren Mannschaften spielen in der Super Bowl haben eine Zunahme der Todesfälle aufgrund von Grippe in diesem Jahr - Fußball-Fans in Denver und Charlotte könnte besond
  • Die Psychologie der Warum Klimawandel Die Bemühungen der Regel scheitern

    Die Psychologie der Warum Klimawandel Die Bemühungen der Regel scheitern
    Während die Welt auf den letzten, schrecklichen Tragödien vernietet ist, die das Leben von Dutzenden in San Bernardino und Paris senselessly beansprucht, eine weit tödlicher Bedrohung erhält weit weniger Berichterstattung in den Nachrichten - Klimawa
  • Wie CPR wurde so populär,

    Wie CPR wurde so populär,
    Medizinische Kriechen passiert, wenn Ärzte praktizieren "außerhalb der Box." Sie führen Verfahren oder verschreiben Behandlungen in Ermangelung einer klaren Hinweise darauf, dass Patienten profitieren werden. Verwenden Sie zum Beispiel Ärzte oft